5,720VIEWS
(Natural News) In her latest episode of Freedom Force Battalion,
Melissa Redpill shares her latest takes on current events
One of the topics that Redpill takes on is the exposure of what’s been going on in hospitals. A nurse from the U.S. Department of Health and Human
Services (HHS) claimed that a man came to the hospital a few
days after his second dose of the vaccine with shortness of breath. He had to
be put on a ventilator as his lungs started to shut down.
In a video, the nurse interviewed a doctor from the HHS, who told her
that “the government doesn’t want to show that the darn vaccine is full of
sh*t.”
Hospitals use non-approved drug on COVID-19 patients
Hospitals have also been using a non-approved drug, remdesivir, for
COVID-19 patients. Remdesivir is a drug known to stop kidneys from functioning.
A study showed that in a clinical trial, kidney injury occurred in 22.8
percent of patients, and proved to be the most frequent cause of the
discontinuation of the treatment. The most reported effects of remdesivir in COVID-19 patients include kidney injury, renal impairment,
renal failure, and renal tubular necrosis.
In a separate study, 62 percent of COVID-19 patients have been found to
have viral pneumonia,
but over a tenth of them present with bacterial pneumonia. Viral pneumonia is
more frequent in the remdesivir group. The use of remdesivir failed to reduce
the 14-day mortality rates compared to the control groups.
The World Health Organization itself issued
a conditional recommendation against the use of
remdesivir in hospitalized patients, as there
is no real evidence that it improves survival or other outcomes in COVID-19
patients.
Evidence suggested that there is no important effect on mortality, need
for ventilation, time to clinical improvement, or other patient-important
outcomes with the use of remdesivir, yet hospitals have been giving them to
patients.
The WHO’s guideline development group recognized that more research is
needed because there is not enough evidence to support the use of remdesivir
for severely affected COVID-19 patients.
The decision to incorporate remdesivir into the treatment of severe
COVID-19 cases was based on reviews gathered by the National Institute for Health and Care
Excellence (NICE), in a prepping analysis of data that is yet
to be peer-reviewed. However, it showed that remdesivir does not show efficacy
in regulating the severity of COVID-19. (Related: Did Fauci knowingly fast-track
approval of drug with deadly COVID-like side effects?)
Project Veritas drops bombshells
Project Veritas does undercover journalism work that exposes the lies of the government, and lately, the big issue has been on vaccines.
A video from Project Veritas featured Jodi O’Malley, a registered
nurse who works for the Indian Health Service in Arizona, and her interview with a doctor named Maria Gonzales. In the video, Gonzales said, “All this is bullshit. Now, [a patient]
probably [has] myocarditis due to the vaccine. But now, they are not going to
blame the vaccine. They are not reporting it. They want to shove it under the
mat.”
There should be little doubt about vaccines — the government is expected
to share with the public fully and completely the complications that arise upon inoculation. With the government instituting mandates around vaccines, it is
important that the population is aware of all the side effects that come with
them, to ensure that they know whether or not it is a good idea for their body.
Catch Melissa Redpill on her Brighteon.TV channel,
Freedom Force Batallion. It airs on BrighteonTV at 11 a.m.
Get more updates about COVID-19, vaccines, and
alternative treatments at Pandemic.news.
Sources include:
-------
WHO recommends against the use of remdesivir in COVID-19 patients
20 November
2020
WHO has issued a conditional recommendation against
the use of remdesivir in hospitalized patients, regardless of disease severity,
as there is currently no evidence that remdesivir improves survival and other
outcomes in these patients.
This recommendation, released on 20 November, is
part of a living guideline on clinical care for COVID-19. It was developed by
an international guideline development group, which includes 28 clinical care experts,
4 patient-partners and one ethicist.
The guidelines were developed in collaboration with
the non-profit Magic Evidence Ecosystem Foundation (MAGIC), which provided
methodologic support. The guidelines are an innovation, matching scientific
standards with the speed required to respond to an ongoing pandemic.
Work on this began on 15 October when the WHO
Solidarity Trial published its interim results. Data reviewed by the panel
included results from this trial, as well as 3 other randomized controlled
trials. In all, data from over 7000 patients across the 4 trials were
considered.
The evidence suggested no important effect on
mortality, need for mechanical ventilation, time to clinical improvement, and
other patient-important outcomes.
The guideline development group recognized that
more research is needed, especially to provide higher certainty of evidence for
specific groups of patients. They supported continued enrollment in trials
evaluating remdesivir.
Updated 20 November 2020
* A conditional recommendation is issued when the evidence around the benefits
and risks of an intervention are less certain. In this case, there is a
conditional recommendation against the use of remdesivir. This means that
there isn’t enough evidence to support its use.
Clinical Pharmacology &
Therapeutics
Brief Report
Free Access
Remdesivir and Acute Renal Failure: A Potential
Safety Signal From Disproportionality Analysis of the WHO Safety Database
Alexandre O. Gérard,Audrey Laurain,Audrey Fresse,Nadège Parassol,Marine Muzzone,Fanny Rocher,Vincent L.M. Esnault,Milou-Daniel Drici,
First
published: 19 December
2020
https://doi.org/10.1002/cpt.2145
Citations: 5
Abstract
Remdesivir is
approved for emergency use by the US Food and Drug Administration (FDA) and
authorized conditionally by the European Medicines Agency (EMA) for patients
with coronavirus disease 2019 (COVID-19). Its benefit-risk ratio is still being
explored because data in the field are rather scant. A decrease of the
creatinine clearance associated with remdesivir has been inconstantly reported
in clinical trials with unclear relevance. Despite these uncertainties, we
searched for a potential signal of acute renal failure (ARF) in
pharmacovigilance postmarketing data. An analysis of the international
pharmacovigilance postmarketing databases (VigiBase) of the World Health
Organization (WHO) was performed, using two disproportionality methods.
Reporting odds ratio (ROR) compared the number of ARF cases reported with
remdesivir, with those reported with other drugs prescribed in comparable
situations of COVID-19 (hydroxychloroquine, tocilizumab, and
lopinavir/ritonavir). The combination of the terms “acute renal failure” and
“remdesivir” yielded a statistically significant disproportionality signal with
138 observed cases instead of the 9 expected. ROR of ARF with remdesivir was
20-fold (20.3; confidence interval 0.95 [15.7–26.3], P < 0.0001])
that of comparative drugs. Based on ARF cases reported in VigiBase, and despite
the caveats inherent to COVID-19 circumstances, we detected a statistically
significant pharmacovigilance signal of nephrotoxicity associated with
remdesivir, deserving a thorough qualitative assessment of all available data.
Meanwhile, as recommended in its Summary of Product Characteristics, assessment
of patients with COVID-19 renal function should prevail before and during
treatment with remdesivir in COVID-19.
